R R

What Is Sabril?

Sabril is a prescription antiseizure medication containing vigabatrin. It is approved as additional treatment for refractory complex partial seizures in adults and children aged two years and older who have not responded adequately to several other treatments. Sabril is also approved as a single medication for infantile spasms in babies and young children aged one month through two years. It is available as oral tablets and powder for oral solution. Vigabatrin increases the availability of an inhibitory neurotransmitter in the brain. Sabril carries a boxed warning for potentially permanent vision loss and is subject to restricted prescribing and distribution requirements.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Sabril?

Sabril is a prescription antiseizure medication containing vigabatrin. It is approved as additional treatment for refractory complex partial seizures in adults and children aged two years and older who have not responded adequately to several other treatments. Sabril is also approved as a single medication for infantile spasms in babies and young children aged one month through two years. It is available as oral tablets and powder for oral solution. Vigabatrin increases the availability of an inhibitory neurotransmitter in the brain. Sabril carries a boxed warning for potentially permanent vision loss and is subject to restricted prescribing and distribution requirements.

read more about sabril ...

Copy this HTML:

Copy HTML Copied!

How Does Sabril Work?

Sabril contains vigabatrin, which irreversibly inhibits GABA transaminase, an enzyme responsible for breaking down gamma-aminobutyric acid, or GABA. GABA is an inhibitory neurotransmitter that helps regulate electrical activity in the brain. By reducing GABA breakdown, vigabatrin increases GABA concentrations and can help suppress certain abnormal electrical signals associated with seizures. Its effects can persist after the medication leaves the bloodstream because the inhibited enzyme must be replaced. This mechanism does not eliminate every cause of epilepsy or infantile spasms. The same treatment can cause retinal toxicity and irreversible visual field loss, requiring close assessment of benefits and risks.

What Types of Seizures Does Sabril Treat?

Sabril is approved as adjunctive therapy for refractory complex partial seizures in adults and children aged two years and older when several alternative treatments have not controlled seizures adequately. It is not a first-line treatment for these seizures. Sabril is also approved as monotherapy for infantile spasms in children aged one month through two years when the expected benefit outweighs the potential for vision loss. Infantile spasms are a serious seizure disorder of early childhood that requires prompt neurological assessment. A specialist evaluates seizure type, previous therapies, visual health, and treatment response before prescribing vigabatrin.

How Should Sabril Be Taken?

Sabril is taken orally, with doses based on seizure type, age, weight, and kidney function. Adults with refractory complex partial seizures commonly begin at 500 mg twice daily, increasing gradually to a recommended dose of 1,500 mg twice daily. Children require weight-based dosing. For infantile spasms, treatment commonly begins at 50 mg/kg daily divided into two doses, with adjustments based on response and tolerability. The powder must be mixed with water according to the product instructions. Vision testing is recommended at baseline, at least every three months during treatment, and approximately three to six months after stopping. If infantile spasms do not improve substantially within two to four weeks, treatment should generally be withdrawn.

What Are the Side Effects and Warnings of Sabril?

Sabril carries a boxed warning for permanent bilateral visual field constriction, which can cause tunnel vision and disability. Vision loss may develop without noticeable symptoms, can worsen with cumulative exposure, and may continue after treatment stops. Other adverse effects include sleepiness, fatigue, dizziness, irritability, weight gain, and coordination problems. Serious risks include suicidal thoughts or behavior, peripheral neuropathy, abnormal brain MRI findings in infants, and withdrawal seizures if treatment stops abruptly. Patients require periodic vision monitoring, although testing cannot prevent all damage. Sabril is distributed through the Vigabatrin REMS program. New visual symptoms, severe behavioral changes, or worsening seizures require prompt medical assessment.

Common Questions About Sabril

Is Sabril the same as vigabatrin?

Yes. Sabril is a brand name for vigabatrin, an antiseizure medication used for specific difficult-to-treat seizures and infantile spasms.

Can Sabril cause permanent vision loss?

Yes. Sabril can cause irreversible visual field loss, including tunnel vision. The risk increases with greater cumulative exposure, and no dose is known to be free of this risk.

How frequently should vision be checked during Sabril treatment?

Vision assessment is recommended before treatment or within four weeks of starting, at least every three months during treatment, and approximately three to six months after stopping.

Can contact lenses prevent Sabril-related vision loss?

No. Contact lenses cannot prevent or correct retinal damage caused by vigabatrin. Patients must follow the prescribed ophthalmic monitoring schedule.

References

DailyMed - SABRIL (vigabatrin) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98. Date Accessed November 6, 2026.

DailyMed - SABRIL (vigabatrin) powder for oral solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a88ac1b4-e2c9-45c0-b321-4785902172e3. Date Accessed November 6, 2026.

Vigabatrin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a610016.html. Date Accessed November 6, 2026.

Vigabatrin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Vigabatrin. Date Accessed November 6, 2026.

Vigabatrin REMS. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm. Date Accessed November 6, 2026.